— AstraZeneca Plc (NYSE: AZN) reported its third-quarter 2019 earnings of $0.23 per share and core earnings of $0.99 per share. This is compared to $0.45 per share expected.
— Total revenue increased by 20% to $6.41 billion versus $6.18 billion expected. This is driven by a 16% jump in product sales.
— Oncology sales jumped by 46% and respiratory sales grew by 15%. Biopharmaceuticals sales increased by 12% and new CVRM sales rose by 8% while sales in other medicines fell by 9%.
— Looking ahead into the full year 2019, the company reiterates its core earnings guidance in the range of $3.50 to $3.70 per share.
— The core operating profit for fiscal 2019 is predicted to increase ahead of product sales.
— For the full year, capital expenditure is anticipated to be broadly stable and restructuring expenses are targeted to reduce versus the prior-year.
Most Popular
Intuit (INTU) set to report Q1 FY26 results. Here’s what to expect
Intuit Inc. (NASDAQ: INTU) is preparing to report results for the first three months of fiscal 2026, amid expectations for a double-digit increase in revenues and adjusted earnings. While the
Estee Lauder’s (EL) Beauty Reimagined strategy is paying off, a few points to note
Shares of The Estée Lauder Companies Inc. (NYSE: EL) stayed green on Friday. The stock has gained 20% year-to-date. After going through a challenging phase, the company witnessed a rebound
Omnichannel push, margin dynamics in focus as Walmart gears up for Q3 earnings
Walmart Inc. (NYSE: WMT) entered the second half of FY26 navigating a challenging retail landscape marked by tariff-related cost pressure and cautious consumer behavior. At the same time, the company
